MediWoundの空売り状況は、投資家がMediWoundの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

MediWound (NASDAQ:MDWD) 株価情報, 空売り情報

MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

MediWound Ltd

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital raised the price target for Autodesk, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $287 to $308. BMO Capital analyst Daniel Jester maintained a Market Perform rating. Autodesk shares closed at $317.96 on Tuesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) from $25 to $18. Baird analyst Mark Altschwager downgraded the stock from Outperform to Neutral. Kohl&#8217;s shares closed at $15.22 on Tuesday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) price target from $15 to $17. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Iris Energy shares settled at $9.56 on Tuesday. <a href="https://www.benzinga.com/quote/IEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group boosted The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $62 to $85. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Kroger shares closed at $60.57 on Tuesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised New Jersey Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) price target from $46 to $49. Guggenheim analyst Shahriar Pourreza maintained a Neutral rating. New Jersey Resources shares closed at $50.71 on Tuesday.  <a href="https://www.benzinga.com/quote/NJR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets boosted MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) price target from $80 to $100. Northland Capital Markets analyst Mike Grondahl maintained an Outperform rating on the stock. MoneyLion shares closed at $86.64 on Tuesday. See how other analysts view this stock.</li>
<li>Benchmark cut the price target for H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) from $53 to $48. Benchmark analyst Fawne Jiang maintained a Buy rating. H World shares settled at $33.10 on Tuesday. <a href="https://www.benzinga.com/quote/HTHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup boosted Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) price target from $42 to $59. Citigroup analyst Paul Lejuez upgraded the stock from Neutral to Buy. Urban Outfitters shares closed at $40.14 on Tuesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut the price target for MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) from $28 to $25. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. MediWound shares closed at $16.90 on Tuesday. <a href="https://www.benzinga.com/quote/MDWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) price target from $80 to $90. Needham analyst Mike Cikos maintained a Buy rating. Nutanix shares closed at $72.35 on Tuesday. <a href="https://www.benzinga.com/quote/NTNX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42210452/top-3-consumer-stocks-that-are-set-to-fly-in-q4">Top 3 Consumer Stocks That Are Set To Fly In Q4</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ADSK

HTHT

IREN

MDWD

NTNX

URBN

Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and lowers the price target from $28 to $25.

HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $25

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.45) by 117.78 percent. The company reported quarterly sales of $4.36 million which missed the analyst consensus estimate of $6.01 million by 27.49 percent. This is a 8.81 percent decrease over sales of $4.78 million the same period last year.

Earnings

MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is projected to report quarterly loss at $0.08 per share on revenue of $708 thousand. 
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $164.00 million. 
• Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is expected to report quarterly loss at $0.29 per share on revenue of $194.49 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $9.63 billion. 
• Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $3.71 billion. 
• JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) is estimated to report quarterly earnings at $2.51 per share on revenue of $2.26 billion. 
• Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is expected to report quarterly earnings at $2.69 per share on revenue of $3.03 billion. 
• Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is projected to report quarterly earnings at $1.64 per share on revenue of $2.41 billion. 
• Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $675.30 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $276.88 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $26.70 million. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is estimated to report earnings for its third quarter. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.72 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $2.56 billion. 
• H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is estimated to report quarterly earnings at $0.69 per share on revenue of $933.86 million. 
• Cadeler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDLR#NYSE">CDLR</a>) is likely to report earnings for its third quarter. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $1.18 billion. 
• American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is projected to report quarterly earnings at $2.37 per share on revenue of $458.29 million. 
• Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is projected to report earnings for its third quarter. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is projected to report quarterly loss at $0.44 per share on revenue of $6.01 million. 
<h3>Companies Reporting After The Bell</h3>
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $562.00 million. 
• Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $54.75 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is expected to report quarterly loss at $0.09 per share on revenue of $113.65 million. 
• Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $747.44 million. 
• Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) is projected to report quarterly loss at $0.21 per share on revenue of $30.59 million. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $1.34 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $3.35 billion. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $983.03 million. 
• Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) is estimated to report quarterly earnings at $2.06 per share on revenue of $24.72 billion. 
• Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $572.16 million. 
• Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is expected to report quarterly loss at $0.92 per share on revenue of $58.91 million. 
• Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is likely to report quarterly earnings at $2.12 per share on revenue of $1.56 billion. 
• Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) is projected to report quarterly earnings at $1.76 per share on revenue of $2.13 billion. 
• Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $79.03 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is likely to report earnings for its third quarter. 
• Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its third quarter. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $116.39 million. 
• HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is expected to report quarterly earnings at $0.93 per share on revenue of $14.00 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBA

AMWD

ARWR

BURL

CDLR

CRWD

DELL

EMBC

ICCM

MANU

NOAH

PNST

TITN

WDAY

Earnings Scheduled For November 26, 2024

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MediWound to report an earnings per share (EPS) of $-0.44.
The announcement from MediWound is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.24 in the last quarter, leading to a 4.01% increase in the share price on the following day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.41</td>
<td>-0.23</td>
<td>-0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-0.39</td>
<td>-0.19</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732550447_0.png" alt="eps graph" />
<h3>Performance of MediWound Shares</h3>
Shares of MediWound were trading at $16.48 as of November 22. Over the last 52-week period, shares are up 96.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: MediWound

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $28 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target

EscharEx against collagenase ointment (marketed as SANTYL in the U.S. and IRUXOL in Europe)&nbsp;

Health Care

General

Mediwound Will Initiate A Controlled, Multicenter Phase 2 Study For EscharEx Against Collagenase Ointment For Venous Leg Ulcers. Scheduled To Commence In 2025, This Phase 2 Study Will Run Concurrently With The Company's Phase 3 Trial

Biotech

MediWound NexoBrid For Treatment Pediatric Patients With Severe Thermal Burns Approved By FDA

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.44) by 54.55 percent. This is a 780 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $5.06 million which met the analyst consensus estimate. This is a 6.08 percent increase over sales of $4.77 million the same period last year.

Earnings Misses

MediWound Q2 Adj $(0.68) Misses $(0.42) Estimate, Sales $5.06M Inline

AST SpaceMobile (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) is set to report its second-quarter 2024 results on Aug 14, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 11.11%, with the bottom line beating the Zacks Consensus Estimate by 2 cents. The company is expected to report a top-line improvement year over year, backed by healthy momentum in both the government and private sector.
<h3>Factors at Play</h3>
During the quarter, AST SpaceMobile inked a definitive commercial agreement with AT&amp;T. Per the deal, AT&amp;T is set to leverage ASTS&#39; Space-based direct-to-mobile technology to deliver seamless and reliable connectivity to consumers and expand coverage into remote, rural and hard-to-reach locations across the continental United States.
Verizon, another major player in the U.S. telecom industry, also signed a deal with the company to deliver seamless connectivity to remote corners of the country utilizing ASTS&#39; satellite network. Its commercial communication technologies are also gaining traction in the government sector for mission-critical applications. These developments will likely have a favorable impact on the company&#39;s earnings.
For the June quarter, the Zacks Consensus Estimate for total revenues is pegged at $2 million. The company didn&#39;t generate any revenues from in the second quarter of fiscal 2023.&nbsp;
The consensus estimate for adjusted earnings per share indicates a loss of 19 cents per share. It incurred a loss of 24 cents per share in the year-ago quarter.
<h3>Earnings Whispers</h3>
Our proven model does not conclusively predict an earnings beat for AST SpaceMobile this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%.
<div class="chart_embed">
<h3>AST SpaceMobile, Inc. Price and EPS Surprise</h3>
<img alt="AST SpaceMobile, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/e8/1723470331.png" style="height:298px; width:610px" title="" />
AST SpaceMobile, Inc. price-eps-surprise | AST SpaceMobile, Inc. Quote
Zacks Rank: AST SpaceMobile currently has a Zacks Rank #3.
</div>
<h3>Stocks to Consider</h3>
Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
MediWound Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdwd#NASDAQ">MDWD</a>) is set to release quarterly numbers on Aug 14. It has an Earnings ESP of +4.76% and a Zacks Rank #2.
On Holding AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) is scheduled to report quarterly numbers on Aug 13. It has an Earnings ESP of +11.51% and sports Zacks Rank of 1.
The Earnings ESP for Dycom Industries (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dy#NYSE">DY</a>) is +4.43%, and it has a Zacks Rank of 3. The company is scheduled to report quarterly numbers on Aug 21.
<a href="https://www.zacks.com/stock/news/2320784/ast-spacemobile-asts-to-post-q2-earnings-what-s-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2320784">To read this article on Zacks.com click here.</a>

Mid Cap

ASTS

ONON

AST SpaceMobile to Post Q2 Earnings: What's in the Cards?

MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the positive results of the NEXT&mdash;an Expanded Access Protocol. NEXT, initiated in 2019, aimed to ensure the continuous availability of NexoBrid&reg;&nbsp;in burn centers until its commercialization. This program successfully maintained physician expertise, provided burn victims with ongoing access to this life-saving treatment, and facilitated the accumulation of real-world safety and clinical data for NexoBrid. 
&nbsp;
Jeremy Goverman, MD, FACS, Associate Professor of Surgery at Harvard Medical School, commented, &quot;The NEXT results reaffirm the significant benefits of NexoBrid in managing severe burns. This enzymatic debridement agent accelerates the debridement process and reduces the need for surgical interventions, ultimately enhancing patient outcomes. The findings from NEXT are consistent with data from the DETECT and CIDS Phase III trials, reinforcing the critical role that NexoBrid should play in standard burn care protocols.&quot;
NEXT, an open-label, single-arm treatment protocol was conducted at 29 burn centers across the U.S. 239 patients, including 215 adults and 24 children, with deep partial and full-thickness thermal burns covering up to&nbsp;30%&nbsp;of the total body surface area (TBSA) were treated with NexoBrid.
Key Results of the NEXT Protocol Include:
<ul>
<li>Efficacy&nbsp;(findings were consistent with Phase III studies results):
<ul>
<li>94.9%&nbsp;of adults and&nbsp;100%&nbsp;of children achieved complete debridement.</li>
<li>Only&nbsp;4.2%&nbsp;of adults required surgical excision for eschar removal after NexoBrid treatment, and none in the pediatric group.</li>
<li>The mean (&plusmn; SD) percent of wound area surgically excised for adults was&nbsp;3.6%&nbsp;(&plusmn;18.33), and&nbsp;0%&nbsp;for children.</li>
<li>The time to complete eschar removal was less than one day for both adults and children.</li>
</ul>
</li>
<li>Healing and Hospitalization:
<ul>
<li>The median time to wound closure was 22 days (95%&nbsp;CI: 22, 23) for adults and 28 days (95%&nbsp;CI: 18, 32) for children.</li>
<li>The median time of hospitalization duration was 10 days (95%&nbsp;CI: 8, 11) for adults and 10 days (95%&nbsp;CI: 5, 14) for children.</li>
</ul>
</li>
<li>Safety:&nbsp;The safety data was consistent with the established safety profile of NexoBrid, and no new safety concerns were identified by the Data Safety and Monitoring Board (DSMB).</li>
<li>Benefit-Risk Ratio:&nbsp;The overall benefit-to-risk ratio of NexoBrid treatment remains favorable.</li>
</ul>

MediWound Announces Results from NEXT Protocol for NexoBrid in Burn Treatment

MediWound (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdwd#NASDAQ">MDWD</a>) closed the last trading session at $18.89, gaining 21.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.75 indicates a 57.5% upside potential.
The average comprises four short-term price targets ranging from a low of $25 to a high of $36, with a standard deviation of $4.65. While the lowest estimate indicates an increase of 32.4% from the current price level, the most optimistic estimate points to a 90.6% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for MDWD, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company&#39;s ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn&#39;t gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
<h2>Here&#39;s What You Should Know About Analysts&#39; Price Targets</h2>
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company&#39;s fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock&#39;s price movement. While that doesn&#39;t necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
<h2>Here&#39;s Why There Could be Plenty of Upside Left in MDWD</h2>
There has been increasing optimism among analysts lately about the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 3.6%, as one estimate has moved higher compared to no negative revision.
Moreover, MDWD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock&#39;s potential upside in the near term.
Therefore, while the consensus price target may not be a reliable indicator of how much MDWD could gain, the direction of price movement it implies does appear to be a good guide.
<a href="https://www.zacks.com/stock/news/2313033/can-mediwound-mdwd-climb-57-49-to-reach-the-level-wall-street-analysts-expect?cid=CS-BENZ-FT-tale_of_the_tape|consensus_price_target-2313033">To read this article on Zacks.com click here.</a>

Can MediWound Climb 57.49% to Reach the Level Wall Street Analysts Expect?

Research Published in THE LANCET's eClinicalMedicine EscharEx&#xAE; Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue
YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), the global leader in next-generation enzymatic therapeutics for tissue repair, today announces the peer-reviewed publication on the Phase II ChronEx study assessing the safety and efficacy of EscharEx for the treatment of Venous Leg Ulcers (VLU) in the prestigious eClinicalMedicine, a journal under <a href="https://www.globenewswire.com/Tracker?data=rkbDHM4MEzdrcnomm966J3t9KTqMcg_KQVFghCQfCsHer9lLhY6iOMhcODxFOfCAgXbqCWywd4pLKW4R00S6YvODjyeqNxL5Iqe-4z5YrKdePNy9MU_EHVHer6FSrBiO">THE LANCET Discovery Science</a> umbrella. The publication, titled "Once daily Bromelain-based enzymatic debridement of venous leg ulcers versus gel vehicle (placebo) and non-surgical standard of care: a three-arm multicenter, double-blinded, randomized controlled study", reports the <a href="https://www.globenewswire.com/Tracker?data=caUVCaSLRovkyIwZXgOowaJGuqxaWtxwuLG_ebE-2DV6LY86uHnLqtULT9rF_1bHnswzpNTfHu3b24P4yEZUgbagvE-RXs5TSfKfs0qyF5FGQdqP18kCnZOHyMzpMO6qWp4QaQR25YAJbxSZjb4oNJWmrqQbmjSSQR92Szs7vX0=">results of the study</a>.

MediWound Announces Publication Of The EscharEx Phase II ChronEx Study Results For Venous Leg Ulcers In THE LANCET's eClinicalMedicine

MediWound Selected For €16.25M Funding From The European Innovation Council Accelerator Program

Legal

TEVA

MediWound Files Amendment To Settlement Agreement With Teva; Under Amendment, Co Will Prepay Teva $4M As Final Payment Due From Company Under Agreement; 50% Of Prepayment In Cash, 50% In Form Of Ordinary Shares Of Co To Be Issued By Co To Teva

M&ouml;lnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US&nbsp;$15m&nbsp;in MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). MediWound, a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement, has a vision to improve the existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
Debridement is a standard of care step to prepare the wound bed for healing and can help in the management of infection. It involves the removal of dead or devitalised tissue from a wound.

Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions

MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including M&ouml;lnlycke&nbsp;Health Care (&quot;M&ouml;lnlycke&quot;), a world-leading MedTech company specializing in solutions for wound care and surgical procedures. 
&nbsp;
The agreement includes the sale and purchase of 1,453,488 shares of the Company&#39;s ordinary shares, each with a par value NIS 0.07 (the &quot;Ordinary Shares&quot;), in a private investment in public equity (the &quot;PIPE Offering&quot;). The purchase price is set at&nbsp;$17.20&nbsp;per share. The gross proceeds from the PIPE Offering are&nbsp;$25 million. MediWound plans to use the net proceeds to advance EscharEx pre-commercial activities, expedite the development of large-scale manufacturing capabilities specifically for EscharEx, and support general corporate purposes. The PIPE Offering is expected to close within several days, subject to satisfaction of customary closing conditions.

Offerings

MediWound Announces $25M Strategic Private Placement Financing Of 1.45M Shares At $17.20/Share To Advance EscharEx Pre-Commercial Activities

Shares of NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family <a href="https://www.benzinga.com/markets/equities/24/07/39645086/leadership-change-at-nio-cfo-resigns-senior-vp-takes-charge">reasons, effective July 5, 2024</a>.
NIO shares dipped 8.5% to $4.4550 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) jumped 120% to $0.3870 after gaining 6% on Wednesday.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) rose 70.5% to $4.65 after gaining around 14% on Wednesday.</li>
<li>MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) shares climbed 41.7% to $15.07, possibly on continued retail investor interest.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) gained 27% to $1.06.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) jumped 19.8% to $3.38.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) climbed 17.7% to $27.85.</li>
<li>Annovis Bio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) rose 14.1% to $9.22.</li>
<li>CleanCore Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#NYSE">ZONE</a>) surged 13% to $2.60.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) climbed 12.6% to $3.9750.</li>
<li>Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) gained 11.9% to $7.22.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 11.6% to $7.60.</li>
<li>Macy&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) gained 10.4% to $19.79. An investor group aiming to purchase Macy's has reportedly increased its bid for the second time after previous offers failed. Arkhouse Management and Brigade Capital Management recently raised their proposal by approximately $300 million, reported The Wall Street Journal.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) rose 9.8% to $0.5379.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) rose 9.3% to $0.2514 after the company announced it received two purchase orders for a total of approximately one million SecureGard syringes for 2024 delivery.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) gained 7.4% to $180.54.</li>
<li>Smith &amp; Nephew plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) rose 7.2% to $26.93 after a Form6 filing showed Cevian Capital II GP Limited reported a 5.021046% stake in the company.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Adamas One Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEWL#NASDAQ">JEWL</a>) shares dipped 20.8% to $0.3660 after gaining 89% on Wednesday.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dipped 20% to $4.30.</li>
<li>Eshallgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) fell 19.2% to $2.11. Eshallgo closed $5 million initial public offering at $4 per share.</li>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) fell 18.3% to $0.4606.</li>
<li>Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) dipped 16.4% to $17.77.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) fell 15% to $1.24.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) declined 14.1% to $0.1550.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) fell 12.4% to $2.3450.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) declined 11.4% to $15.60.</li>
<li>Shapeways Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) dipped 11.1% to $0.24.</li>
<li>Inseego Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) fell 11.1% to $10.40.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) declined 10% to $7.49. The company announced vehicle delivery figures for June and the first half of 2024 on Monday.</li>
<li>HDFC Bank Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) dipped 7.7% to $61.49.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares fell 7.1% to $0.17. Zoomcar Holdings shares jumped 34% on Wednesday after the company announced that it expects an increase in its FY24 total revenue and decline in its FY24 net loss.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) declined 7.1% to $15.74.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) declined 6.5% to $19.61 amid weakness in Bitcoin.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) fell 6.1% to $11.11 amid a decline in Bitcoin prices.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) fell 6.1% to $15.18 after the company its operations update for June 2024.</li>
<li>Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) shares declined 5.9% to $13.53. Iris Energy announced on Tuesday that it has secured $413 million to fuel its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining expansion.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares fell 4.5% to $6.47 after gaining around 7% on Wednesday. B. Riley Securities analyst Lucas Pipes, last week, maintained Applied Digital with a Buy and raised the price target from $6 to $8.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39646821/how-to-earn-500-a-month-from-nvidia-stock">How To Earn $500 A Month From Nvidia Stock</a>

Intraday Update

Movers

$BTC

ANVS

APLD

BTDR

CNSP

CSTL

EHGO

INSG

JEWL

KOSS

MARA

MESO

PRTG

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RILY

RNAC

RYDE

SHPW

SIRI

SISI

SPWR

STSS

XPEV

ZAPP

ZCAR

ZONE

Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

MediWound Is A Healthy Investment

MediWound Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

MediWound GAAP EPS of -$0.98 misses by $0.53, revenue of $4.35M misses by $1.66M

Reports Q3 revenue $4.355M, consensus $6.01M. "We made great headway toward our objectives this quarter, achieving a major milestone with NexoBrid ...

MediWound reports Q3 EPS (98c), consensus (44c)

Mediwound (MDWD) has released an update. MediWound has reported a significant milestone with FDA approval for pediatric use of its burn treatment, ...

MediWound Advances with FDA Approval and New Funding

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Mediwound (MDWD – Research Report) and keeping the price target at $25.00. Josh Jenn...

Mediwound's Promising Outlook: Expansion and Trials Support Buy Rating

Mediwound ( ($MDWD) ) has released its Q3 earnings. Here is a breakdown of the information Mediwound presented to its investors. MediWound Ltd., a ...

MediWound Advances Enzymatic Therapeutics Amid Financial Shifts

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on MediWound (MDWD) to $25 from $28 and keeps a Buy rating on the sh...

MediWound price target lowered to $25 from $28 at H.C. Wainwright

Press Releases

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound to Report Second Quarter 2024 Financial Results

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound to Report Third Quarter 2024 Financial Results

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Comments

MediWound

空売り

MediWound (NASDAQ:MDWD) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル